Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial
The Lancet. Respiratory medicine（2024）
摘要
Parion Sciences, under agreement with Vertex Pharmaceuticals.
更多查看译文
关键词
primary ciliary dyskinesia,sodium channel,clean-pcd,double-blind,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要